All In Biotech

BLA 761059 · Samsung Bioepis CO LTD

Hadlima

Adalimumab-Bwwd · Injection · Tumor Necrosis Factor Blocker

Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jul 23, 2019

Approved uses

5

Original approval plus efficacy supplements

Registered trials

523

198 Phase 3, 51 recruiting

FAERS reports

10

4 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products including HADLIMA, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue HADLIMA if a patient develops a serious infection or sepsis. Reported infections include: • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HADLIMA use and during therapy. Initiate treatment for latent TB prior to HADLIMA use. • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and...

What it is approved for

From the label in effect Oct 28, 2026.

HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ( 1.1 ) . • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older ( 1.2 ). • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis ( 1.3 ). • Reducing signs and symptoms in adult patients with active ankylosing spondylitis ( 1.4 ). • Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older ( 1.5 ) . • Treatment of moderately to severely active ulcerative colitis in adult patients ( 1.6 ) . Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) . • Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) . • Treatment of non-infectious intermediate, posterior, and panuveitis in adult patients ( 1.9 ) . 1.1 Rheumatoid Arthritis HADLIMA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HADLIMA can be used alone or in combination with methotrexate or...

Mechanism: Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • HADLIMA · ADALIMUMAB-BWWD 40MG/0.8ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Adalimumab" as an intervention, any sponsor and status, largest first.

All 523 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity2
  • injection site pain2
  • tachypnoea2
  • drug ineffective1
  • general physical health deterioration1
  • headache1
  • influenza like illness1
  • pain1
  • rash pruritic1
  • rash pustular1
  • tachycardia1
  • therapy interrupted1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20245
20253
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Hadlima (Adalimumab-Bwwd)

2024 spending

$295K

Beneficiaries

70

278 claims

Per beneficiary

$4,213

$626.96 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$14,476
2024$294,922

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,625 on PubMed

Sponsor: Samsung Bioepis CO LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.